Stockscreener 앱 받기
0.00
100.00%
-8.28
시간 외 거래:
8.45
8.45
+
Cybin Inc 주식(CYBN)의 최신 뉴스
Profit Review: Can Brookfield Renewable Corporation disrupt its industry2025 Earnings Surprises & Verified Momentum Stock Alerts - baoquankhu1.vn
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Published on: 2026-02-25 04:37:15 - baoquankhu1.vn
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Published on: 2026-02-24 19:40:53 - baoquankhu1.vn
Former Pfizer chief medical officer joins Helus mental health push - Stock Titan
Moving Averages: What hedge funds are buying Cybin IncJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Day Trade: What is PFBCs revenue forecastJuly 2025 Sentiment & Risk Controlled Swing Alerts - baoquankhu1.vn
What are Cybin Inc.’s earnings expectationsWeekly Risk Summary & Low Volatility Stock Suggestions - mfd.ru
New Highs: What hedge funds are buying Cybin IncGap Up & Long-Term Growth Stock Strategies - baoquankhu1.vn
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail
(CYBN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers - Yahoo Finance
Cybin stock surges after positive Phase 2a trial results for depression drug - Investing.com
Cybin Inc.Common Stock (Nasdaq:HELP) Stock Quote - The Chronicle-Journal
Helus gains on published data for psychedelic drug (HELP) - Seeking Alpha
Cybin stock surges after positive Phase 2a trial results for depression drug By Investing.com - Investing.com South Africa
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Investing News Network
Single-dose DMT eases major depression in trial published in Nature Medicine - Stock Titan
Breakout Watch: Is Cybin Inc stock a hidden gemJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Here's Why We're Watching Cybin's (NASDAQ:HELP) Cash Burn Situation - Yahoo Finance
Is Cybin Inc. a cyclical or defensive stockSwing Trade & Low Risk Entry Point Guides - mfd.ru
What are Cybin Inc.’s recent SEC filings showing2025 Institutional Moves & High Accuracy Trade Alerts - mfd.ru
Travel Stocks: Is Cybin Inc forming a bullish divergenceQuarterly Market Summary & High Win Rate Trade Alerts - baoquankhu1.vn
Cybin (NASDAQ:HELP) Announces Earnings Results - MarketBeat
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Investing News Network
Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks
Helus Pharma (NASDAQ: HELP) widens loss while sharply increasing cash - Stock Titan
Published on: 2026-02-13 13:41:22 - mfd.ru
Can Cybin Inc. benefit from deglobalizationJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - mfd.ru
Published on: 2026-02-12 21:19:30 - mfd.ru
Fed Meeting: Is Cybin Inc impacted by rising ratesStock Surge & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Ideas Watch: Is Cybin Inc impacted by rising rates2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Is Cybin Inc. forming a breakout pattern2025 Trading Recap & Free Weekly Watchlist of Top Performers - mfd.ru
Will Cybin Inc. Common Shares stock benefit from sector leadershipDay Trade & Fast Entry and Exit Trade Plans - mfd.ru
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution - wahanariau.com
Helus Pharma Appoints Michael Cola as Chief Executive Officer, Effective February 10, 2026 - marketscreener.com
New Helus Pharma CEO inherits mental health drug pipeline at key trial dates - Stock Titan
Will Helus Pharma's GAD Trial Data Calm Investor Anxiety? - RTTNews
How (CYBN) Movements Inform Risk Allocation Models - Stock Traders Daily
Bank Watch: Will Cybin Inc stock benefit from M AJuly 2025 Trends & High Win Rate Trade Tips - baoquankhu1.vn
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Jefferies Financial Group Begins Coverage on Cybin (NASDAQ:HELP) - MarketBeat
Jefferies Initiates Coverage on Cybin With Buy Rating, CA$29.88 Price Target - marketscreener.com
Trend Recap: Does Cybin Inc stock have upside surprise potential2025 Top Gainers & Risk Controlled Stock Alerts - baoquankhu1.vn
Risk Report: Is PRCH stock technically oversoldExit Point & Smart Investment Allocation Tips - baoquankhu1.vn
Market Review: Does Cybin Inc stock have upside surprise potentialJuly 2025 Action & Reliable Entry Point Alerts - baoquankhu1.vn
0.11%
0.59%
자본화:
|
볼륨(24시간):